Selective oestrogen receptor modulators effectively reduce breast cancer in women at moderate to high risk, so why aren’t they being discussed routinely?
Using medication to prevent breast cancer in women at moderate and high risk is a cost-effective1 and immediately implementable strategy for reducing the burden of breast cancer in Australia. There is Level 1 (strong) evidence that selective oestrogen receptor modulators (SERMs) such as tamoxifen and raloxifene reduce breast cancer risk by up to 40% in these women.2 The absolute risk reduction depends on an individual’s risk factor profile.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
We thank Alison Trainer for her critical review of the manuscript. Kelly-Anne Phillips is the Dr John Colebatch Clinical Research Fellow of the Cancer Council, Victoria.
No relevant disclosures.